BA
TEVA icon

Bridgewater Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Bridgewater Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
6,360
+348
+6% +$11.6K 0.01% 454
2026
Q1 		$218K Buy
+6,012
New +$193K 0.01% 430

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bridgewater Advisors's TEVA Position: Q2 2026 in Review

Bridgewater Advisors increased its Teva Pharmaceuticals (TEVA) stake by 5.8% in Q2 2026, buying an estimated $11.6K and bringing the position to 6,360 shares worth $219K. The position accounts for 0.01% of the portfolio, ranked #454.

Bridgewater Advisors first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Bridgewater Advisors held 6,360 shares of Teva Pharmaceuticals worth $219K as of Q2 2026.
  • Bridgewater Advisors bought 348 Teva Pharmaceuticals shares in Q2 2026, an estimated $11.6K.
  • Teva Pharmaceuticals made up 0.01% of Bridgewater Advisors's portfolio in Q2 2026, its #454 holding.
  • Bridgewater Advisors first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Bridgewater Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.